Key clinical point: Real-world endpoints for immunotherapy-treated advanced NSCLC can likely be used to support regulatory and payer decisions.
Major finding: Real-world intermediate endpoints (time to treatment discontinuation, time to next treatment) were moderately to highly correlated with real-world overall survival (correlation coefficients, 0.36 to 0.89), and real-world overall survival mirrored trial overall survival.
Study details: Retrospective cohort study using six data sets from administrative claims and electronic health records to assess endpoints among 13,639 patients with advanced NSCLC treated with PD-1/PD-L1 inhibitors in real-world settings.
Disclosures: Dr. Stewart disclosed no conflicts of interest. The study was supported in part by the National Cancer Institute and the Patient Centered Outcomes Research Institute.
Stewart M et al. JCO Clin Cancer Inform. 2019 July 23. doi: 10.1200/CCI.18.00155.